Istampoulouoglou Ioanna, Zimmermanns Barbara, Grandinetti Tanja, Marzolini Catia, Harings-Kaim Annette, Koechlin-Lemke Sarah, Scholz Irene, Bassetti Stefano, Leuppi-Taegtmeyer Anne B
Department of Clinical Pharmacology & Toxicology, University Hospital Basel, Switzerland.
University of Basel, Basel, Switzerland.
Glob Cardiol Sci Pract. 2021 Jun 30;2021(2):e202111. doi: 10.21542/gcsp.2021.11.
In this article we summarize the cardiovascular adverse events that were observed in three patients during their treatment for COVID-19 and discuss their association with lopinavir/ ritonavir (LPV/r) and hydroxychloroquine (HCQ). The cases were reported to our regional pharmacovigilance centre in April 2020. All three patients were above 75 years in age, male and multimorbid, and had been hospitalized for treatment of COVID-19. As part of their treatment, all of them received a very strictly monitored off-label therapy with LPV/r and HCQ, for which they had given their prior, written, informed consent. In one patient, erythromycin was also administered. All three patients developed a significant QTc time prolongation during or shortly after therapy with the above drugs. On account of this, the treatment had to be discontinued early in each case and QTc time recovered in all three patients.
在本文中，我们总结了3例新冠肺炎患者治疗期间观察到的心血管不良事件，并讨论了这些事件与洛匹那韦/利托那韦（LPV/r）和羟氯喹（HCQ）的关联。这些病例于2020年4月报告给我们地区的药物警戒中心。所有3例患者均为75岁以上男性，患有多种疾病，因新冠肺炎住院治疗。作为治疗的一部分，他们均接受了非常严格监测的LPV/r和HCQ超说明书治疗，他们均已事先签署书面知情同意书。其中1例患者还使用了红霉素。所有3例患者在使用上述药物治疗期间或治疗后不久均出现显著的QTc间期延长。因此，每种情况下治疗均不得不提前中断，且所有3例患者的QTc间期均恢复正常。
